Core Viewpoint - Company is rated "Buy" by Guotai Junan Securities, highlighting its position as a leading global preclinical CRO and biotechnology firm with strong technical barriers and stable revenue growth from preclinical products and services [1] Group 1: Revenue Growth and Business Model - Preclinical products and services are the foundation of the company's business, with revenue growing rapidly; model animal sales are projected to increase from 66 million yuan in 2021 to 389 million yuan in 2024, with a CAGR exceeding 50% [1] - The company has established long-term partnerships with over 950 global collaborators, including the top ten pharmaceutical companies, completing over 6,350 drug evaluation projects [1] - The company has a strong overseas presence, with higher average order values from international clients compared to domestic ones, enhancing its risk resistance and profitability [1] Group 2: Antibody Development and Growth Engine - The "Thousand Mice and Ten Thousand Antibodies" plan is entering a realization phase, with antibody development and licensing becoming a significant growth driver; revenue from antibody development is expected to grow from 127 million yuan in 2022 to 318 million yuan in 2024, with a CAGR of 58% [2] - The company’s innovative "antibody shelf" model breaks traditional efficiency bottlenecks in antibody development, providing high-quality antibody molecules for global partners and maximizing technical value through various collaboration models [2] - The core pipeline focuses on high-value areas, complementing collaborative pipelines and gradually realizing commercial potential, thus creating a new growth engine [2] Group 3: Catalysts - Sales of model animals are expected to exceed forecasts, and the antibody licensing business is anticipated to realize results beyond expectations [3]